Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia

Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia

Disease relapse is the major cause of treatment failure after allogeneic stem cell transplantation (allo-SCT) in acute myeloid leukemia (AML). To identify AML-associated genes prognostic of AML relapse post–allo-SCT, we resequenced 35 genes in 113 adults at diagnosis, 49 of whom relapsed. Two hundre...

Full description

Bibliographic Details
Main Authors:	Quek, L, Ferguson, P, Metzner, M, Ahmed, I, Kennedy, A, Garnett, C, Jeffries, S, Walter, C, Piechocki, K, Timbs, A, Danby, R, Raghavan, M, Peniket, A, Griffiths, M, Bacon, A, Ward, J, Wheatley, K, Vyas, P, Craddock, C
Format:	Journal article
Language:	English
Published:	American Society of Hematology 2016

Similar Items

Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia
by: Lynn Quek, et al.
Published: (2016-12-01)

NGS IDENTIFIES MUTATIONS PROGNOSTIC OF RELAPSE AFTER ALLO-SCT AND NOVEL CLONE EMERGENCE AT DISEASE RECURRENCE: IMPLICATIONS FOR STRATEGIES TO PREVENT POST ALLO-SCT RELAPSE
by: Quek, L, et al.
Published: (2016)

Molecular predictors of response to azacitidine therapy: the results of the UK trials acceleration programme RAVVA study
by: Craddock, C, et al.
Published: (2017)

NIH consensus chronic GvHD following T-replete reduced-intensity conditioning sibling allograft usually develops within a year, causes prolonged morbidity but low mortality and is influenced by prophylactic methotrexate dose
by: Medd, P, et al.
Published: (2010)

Outcome of azacitidine therapy in acute myeloid leukemia is not improved by concurrent vorinostat therapy but is predicted by a diagnostic molecular signature
by: Craddock, C, et al.
Published: (2017)

Vorinostat does not improve outcome in patients with acute myeloid leukemia and high risk myelodysplasia treated with azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial
by: Craddock, C, et al.
Published: (2016)

Classic and overlap chronic graft-versus-host disease after T-replete reduced intensity conditioned sibling allograft usually starts within a year, causes prolonged morbidity but low mortality and is influenced by prophylactic methotrexate and ciclosporin dosing
by: Medd, P, et al.
Published: (2010)

Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy
by: Loke, J, et al.
Published: (2021)

Prognostic value of monitoring a candidate immunophenotypic leukaemic stem/progenitor cell population in patients allografted for acute myeloid leukaemia.
by: Bradbury, C, et al.
Published: (2014)

Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage.
by: Quek, L, et al.
Published: (2016)

Methotrexate dose delivery is more important than ciclosporin level in graft-versus-host disease prophylaxis following T-replete reduced-intensity sibling allogeneic stem cell transplant
by: Medd, P, et al.
Published: (2011)

Methotrexate dose delivery is more important than ciclosporin level in graft-versus-host disease prophylaxis following T-replete reduced-intensity sibling allogeneic stem cell transplant.
by: Medd, P, et al.
Published: (2011)

Quantitation of Leukemic Stem Cell Populations Predicts Clinical Outcome in Acute Myeloid Leukaemia
by: Craddock, C, et al.
Published: (2011)

Meniscal Allograft Transplantation With Concomitant Osteochondral Allograft Transplantation
by: Eric J. Cotter, B.S., et al.
Published: (2017-10-01)

5 ' Azacitidine in Combination with Valproic Acid Induces Complete Remissions in Patients with Advanced Acute Myeloid Leukaemia but Does Not Eradicate Clonal Leukaemic Stem/Progenitor Cells.
by: Craddock, C, et al.
Published: (2008)

5 ' AZACITIDINE IN COMBINATION WITH VALPROIC ACID INDUCES COMPLETE REMISSIONS IN PATIENTS WITH HIGH RISK ACUTE MYELOID LEUKAEMIA BUT DOES NOT ERADICATE CLONAL LEUKAEMIC STEM/PROGENITOR CELLS
by: Craddock, C, et al.
Published: (2009)

Analysis of factors affecting outcome in recipients of bone marrow transplantation for myelodysplasia; a single centre's experience over a nine year period
by: Stoll, V, et al.
Published: (2010)

Clonal heterogeneity in differentiation response and resistance to the IDH2 inhibitor enasidenib in acute myeloid leukemia
by: Quek, L, et al.
Published: (2017)

S237: ORCA-T, AN ENGINEERED ALLOGRAFT, RESULTS IN HIGH GVHD-FREE AND RELAPSE-FREE SURVIVAL FOLLOWING MYELOABLATIVE CONDITIONING FOR HEMATOLOGICAL MALIGNANCIES
by: E. Meyer, et al.
Published: (2022-06-01)

Identification of Novel Recurrent Copy Number Variations and Regions of Copy-Neutral Loss of Heterozygosity by High Resolution Genomic Array in Pre-Treatment and Relapsed B-CLL.
by: Knight, S, et al.
Published: (2009)

Residual Disease Detection by Flow Cytometry Predicts Risk of Relapse and Overall Survival in Patients with Acute Myeloid Leukemia Following Reduced Intensity- and Myeloablative-Allogeneic Hematopoietic Cell Transplantation
by: Bradbury, C, et al.
Published: (2012)

Residual Disease Detection by Flow Cytometry Predicts Risk of Relapse and Overall Survival in Patients with Acute Myeloid Leukemia Following Reduced Intensity- and Myeloablative- Allogeneic Hematopoietic Cell Transplantation
by: Bradbury, C, et al.
Published: (2012)

Patellar Fresh Osteochondral Allograft Transplantation
by: Travis J. Dekker, M.D., et al.
Published: (2019-08-01)

Stem cell transplantation: preventing relapse of transplant
by: Charles Craddock
Published: (2018-06-01)

Impact of Mast Cells in Rejection of Allografts
by: S.K. Kritas, et al.
Published: (2013-09-01)

Heterogeneous genetic and non-genetic mechanisms contribute to response and resistance to azacitidine monotherapy
by: Symeonidou, V, et al.
Published: (2022)

FACTORS DETERMINING CLINICAL RESPONSE TO 5 '-AZACITDINE AND SODIUM VALPROATE COMBINATION THERAPY IN PATIENTS WITH HIGH RISK ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASIA
by: Craddock, C, et al.
Published: (2010)

Differential susceptibility of heart, skin, and islet allografts to T cell-mediated rejection.
by: Jones, N, et al.
Published: (2001)

Pancreas allograft thrombosis.
by: Muthusamy, A, et al.
Published: (2010)

CD25+CD4+ regulatory T cells develop in mice not only during spontaneous acceptance of liver allografts but also after acute allograft rejection.
by: Steger, U, et al.
Published: (2006)

Relapses in patients with a systemic vasculitis.
by: Gordon, M, et al.
Published: (1993)

Measurable residual disease as predictor of post–day +100 relapses after allografting in adult AML
by: Naveed Ali, et al.
Published: (2025-02-01)

Clonal heterogeneity of acute Myeloid Leukemia treated with the IDH2 inhibitor Enasidenib
by: Vyas, P, et al.
Published: (2018)

Arthroscopic Capsule Reconstruction in the Hip Using Iliotibial Band Allograft
by: Christiano A.C. Trindade, M.D., et al.
Published: (2015-02-01)

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia.
by: Vyas, P, et al.
Published: (2015)

Segmental Meniscus Allograft Transplantation
by: Max N. Seiter, M.D., et al.
Published: (2021-03-01)

Fresh Precut Osteochondral Allograft Core Transplantation for the Treatment of Capitellum Osteochondritis Dissecans
by: Sagar Chawla, M.D., M.P.H., et al.
Published: (2020-06-01)

Anemia in renal allograft recipients
by: V. A. Goryainov, et al.
Published: (2018-08-01)

Induction of Immunological Tolerance to Islet Allografts
by: Aldo A. Rossini M.D., et al.
Published: (1996-01-01)

Arthroscopic Superior Capsular Reconstruction With Acellular Dermal Allograft Using Push-In Anchors for Glenoid Fixation
by: William T. Pennington, M.D., et al.
Published: (2019-01-01)